B
Bull
Bull · 25%TOI
$4.41
Szenariopreis
$5.130
+0.285 (+5.56%)Zum Schluss
Loading chart…
- High
- 5.150
- Open
- 4.935
- VWAP
- 5.05
- Vol
- 1.27M
- Mkt Cap
- 33.42M
- Low
- 4.870
- Amount
- 6.39M
- EV/EBITDA, TTM
- -17.68
Starling Oncology, Inc., formerly The Oncology Institute, Inc., is advancing oncology by delivering specialized, value-based cancer care in the community setting. The Company offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with oncology organizations. Its critical services include cancer treatment and infusion centers, in-house dispensary, lab testing, outpatient blood transfusion, financial counseling, end-of-life counseling and comprehensive clinical trials. It treats many forms of cancer, including Acute lymphoblastic leukemia; Acute myeloid leukemia; Bladder cancer; Bone cancer; Brain cancer; Cervical cancer; Choriocarcinoma; Chronic lymphocytic leukemia (CLL); Chronic myeloid leukemia (CML); Skin cancer, and others. It operates over 100 clinics and affiliate locations across multiple states.
AI analysis of Oncology Institute Inc (TOI)
holdOncology Institute Inc (TOI) does not present a strong buy opportunity at this time for a beginner investor with a long-term strategy. While the stock shows some positive technical indicators and analyst optimism, the lack of significant recent news, hedge fund selling trends, and no proprietary trading signals suggest holding off on immediate investment.
Bewertungskennzahlen
The current forward P/E ratio for Oncology Institute Inc (TOI) is 0.00, compared to its 5-year average forward P/E of -7.28.
Alphio AI Price Scenarios for TOI
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding TOI
Event-Zeitleiste
News
9.508-05GlobenewswireTopicus.com Reports Strong Q2 2026 Financial Results
8.507-15NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
8.506-01Yahoo FinanceTopicus Submits Revised Proposal to Acquire ReadyTech
1.005-12GlobenewswireTopicus, Lumine, and Constellation Shareholder Meeting Schedule Announced
9.505-08seekingalphaThe Oncology Institute Q1 2026 Earnings Call Highlights
TOI FAQ — answered by Alphio AI
Starling Oncology, Inc., formerly The Oncology Institute, Inc., is advancing oncology by delivering specialized, value-based cancer care in the community setting. The Company offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with oncology organizations. Its critical services include cancer treatment and infusion centers, in-house dispensary, lab testing, outpatient blood transfusion, financial counseling, end-of-life counseling and comprehensive clinical trials. It treats many forms of cancer, including Acute lymphoblastic leukemia; Acute myeloid leukemia; Bladder cancer; Bone cancer; Brain cancer; Cervical cancer; Choriocarcinoma; Chronic lymphocytic leukemia (CLL); Chronic myeloid leukemia (CML); Skin cancer, and others. It operates over 100 clinics and affiliate locations across multiple states. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).
Oncology Institute Inc (TOI) does not present a strong buy opportunity at this time for a beginner investor with a long-term strategy. While the stock shows some positive technical indicators and analyst optimism, the lack of significant recent news, hedge fund selling trends, and no proprietary trading signals suggest holding off on immediate investment.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.